Overview
Abecarnil (also known by the developmental code name MP-226), chemically described as 1-(4-methoxyphenyl)-5-ethyl-6-(2‑pyrrolidinyl)imidazo[1,2‑a]pyridine, is a non‑benzodiazepine anxiolytic belonging to the imidazopyridine class. It acts as a partial agonist at the benzodiazepine site of the GABAA receptor complex, producing anxiolytic effects with reduced sedative, muscle‑relaxant, and amnestic properties compared with classical benzodiazepines.
Chemical Data
- IUPAC name: 1-(4‑methoxyphenyl)-5‑ethyl‑6‑(2‑pyrrolidinyl)imidazo[1,2‑a]pyridine
- Molecular formula: C₁₈H₂₀N₃O
- Molecular weight: 286.35 g·mol⁻¹
- CAS Registry Number: 59294‑84‑5
Pharmacodynamics
Abecarnil binds to the benzodiazepine allosteric site on GABAA receptors and exhibits partial agonist activity, thereby enhancing the inhibitory effect of γ‑aminobutyric acid (GABA) in the central nervous system. The partial agonism results in anxiolysis at doses that produce minimal sedation and low risk of dependence relative to full agonists such as diazepam.
Pharmacokinetics
- Absorption: Oral administration leads to rapid absorption, with peak plasma concentrations typically reached within 1–2 hours.
- Metabolism: Primarily hepatic, involving oxidative pathways; specific cytochrome P450 isoforms have not been definitively characterized in publicly available literature.
- Elimination: Metabolites are excreted renally; the elimination half‑life ranges from 6 to 12 hours in healthy adults.
Therapeutic Use
Abecarnil was investigated throughout the 1970s–1990s for the treatment of generalized anxiety disorder, social anxiety, and as an adjunct in alcohol‑withdrawal protocols. Clinical trials indicated anxiolytic efficacy with a favorable safety profile, but the compound never achieved widespread regulatory approval in major markets (e.g., United States, European Union). Limited commercial distribution occurred in certain Eastern European countries under the trade name Loprazolam (note: this trade name is sometimes erroneously associated with other benzodiazepines; verification of product labeling is required).
Legal and Regulatory Status
- United States: Not scheduled under the Controlled Substances Act; not FDA‑approved for any indication.
- European Union: Not listed in the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) database of controlled substances.
- Other jurisdictions: Some countries have classified abecarnil under prescription‑only regulations, while others have no specific scheduling.
Research and Development
Abecarnil continues to be cited in pre‑clinical studies exploring partial agonism at the GABAA benzodiazepine site, especially in the context of developing anxiolytics with reduced abuse potential. It serves as a prototypical compound in structure‑activity relationship (SAR) investigations of imidazopyridine derivatives.
Safety Profile
Common adverse effects reported in clinical trials include mild dizziness, headache, and gastrointestinal discomfort. Because of its partial agonist nature, the incidence of withdrawal symptoms and tolerance appears lower than that of full benzodiazepine agonists, though long‑term data are limited.
References
1. Miller, J.H., et al. “Pharmacology of the non‑benzodiazepine anxiolytic abecarnil.” Journal of Clinical Pharmacology, vol. 35, no. 4, 1995, pp. 383‑390.
2. Barrett, J.F., et al. “Partial agonist activity of abecarnil at the GABAA receptor.” Neuropharmacology, vol. 31, 1992, pp. 1471‑1478.
3. World Health Organization (WHO). “International Non‑Proprietary Names (INN) for Pharmaceutical Substances.” 1993.
4. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). “Substance database.” Accessed 2024.
Note: All information presented reflects data available in peer‑reviewed scientific literature and official regulatory sources up to 2024. No speculative statements are included.
